BIT's 16th Annual Congress of International Drug Discovery Science and Technology-2018
Scientific Program
 
BIT's 16th Annual Congress of International Drug Discovery Science and Technology-2018
Theme: Rethinking the Next Big Things in Pharma Innovations
Time: August 16-19, 2018 
Place: Boston Marriott Cambridge, USA
 
Scientific Program
Stream 1 Stream 2 Stream 3 Stream 4 Stream 5

 

Stream 3: Industrial Art Gallery
-Arts in Billion Dollar Molecules and Next Generation Therapy

Substream 3-1: Improved Linear Drug Discovery on Selected Current Drug Targets
Substream 3-2: Novel Small Molecule Inhibitors and Agonists
Substream 3-3: Follow-on Drugs and Repositioning Drug Discovery
Substream 3-4: Novel Biotherapeutic Discovery
Substream 3-5: Smart DDS and Nanomedicine

Substream 3-6: Clinical Trial Gateway and Translational Convergence

Substream 3-7: Arts of Next Generation Therapy

 

Substream 3-6: Clinical Trial Gateway and Translational Convergence
 

Session 3601: Breakthroughs in Clinical Trials & Outsourcing and Integrative Services

Day 2: Morning, Friday, August 17, 2018

Place: Enterprise Room, 3rd Floor

10:10-11:45

Chair: Dr. Greg Miller, Senior Data Scientist, BERG, USA
Time FaceOn Speeches and Speakers
10:10-10:05 Chair's Introduction
10:05-10:25

Title: Drug Resistant HCC and Approaches to Address and Overcome This in the Clinic

Dr. Michael R. Briggs, Woodland Pharmaceuticals LLC; Tufts Cummings School of Veterinary Medicine, USA
10:25-10:45 Title: Artificial Intelligence for De novo Biomarker Discovery in Clinical Trials

Dr. Greg Miller, Senior Data Scientist, BERG, USA

10:45-11:05 Title: Dose Recommendations of a Phase III Pivotal Clinical Study
Dr. Naitee Ting, Director, Department of Biostatistics & Data Sciences, Boehringer-Ingelheim Pharmaceuticals Inc., USA
11:05-11:25 Title: The Effective Outsourcing Process and Strategy: Evaluating Costs, Benefit, Risks and Rewards of Drug Development Outsourcing Strategies
Dr. Lidia Cappellina, Head of R&D Outsourcing Management, Chiesi Group, Italy
11:25-11:45 Title: Effective Approach for Site Selection
Dr. Vladimir Shnaydman, President, ORBee Consulting, USA
12:00-13:00 Lunch

 

Session 3602: Pharmacovigilance, Drug Safety and Risk Management

Day 3: Morning, Saturday, August 18, 2018

Place: Enterprise Room, 3rd Floor

08:30-10:15

Chair: Dr. Vladimir Shnaydman, President, ORBee Consulting, USA
Time FaceOn Speeches and Speakers
08:30-08:35 Chair's Introduction
08:35-09:00 Title: How to Optimize Risk Mitigation Strategy for a Clinical Trial with Limited Budget?
Dr. Vladimir Shnaydman, President, ORBee Consulting, USA
09:00-09:25 Title: Pharma Tech Case Studies, What Went Wrong? – Regulatory Investigations
Dr. P. G. Shrotriya, CEO, Elite Consultancy Services – Pharma Consultant; Director, Pharma Research, School of Pharmacy and Technology Management, SVKM's NMIMS University, India
09:25-09:50

 

Title: Sources of Biases in Studies of Drugs Safety during Pregnancy

Dr. Amalia Levy, Chair, Department of Public Health, Ben-Gurion University of the Negev, Israel

09:50-10:15

Title: Preclinical Integrated Risk Assessment of Suicidal Ideation and Behavior

Dr. Laszlo Urban, Executive Director, Novartis Institutes for BioMedical Research, USA

10:15-10:30 Coffee Break

    

Session 3603: National New Drug R & D Policy and Market Trend

Day 3: Afternoon, Saturday, August 18, 2018

Place: Discovery Room, 3rd Floor

13:30-14:55

Chair: Dr. Niclas Nilsson, Head of RD Open Innovation, LEO Pharma A/S, Denmark
Time FaceOn Speeches and Speakers
13:30-13:35 Chair's Introduction
13:35-13:55 Title: Implementing Open Innovation 2.0 in the Pharmaceutical Drug Research
Dr. Niclas Nilsson, Head of Open Innovation, Research, LEO Pharma, Denmark
13:55-14:15 Title: Research, Breakthroughs, and Reach-through Royalties

Dr. Jason Bryan, Shareholder, Polsinelli, USA

14:15-14:35 Title: Patent Portfolio Development Strategies for Drug Discovery
Dr. Tara Nealey, Shareholder, Vice Chair Biotechnology & Life Sciences Patent Practice, Polsinelli PC, USA
14:35-14:55 Title: The Patent Game: Patent Strategies for Pharmaceutical and Med-Tech Companies
Dr. Vance V. VanDrake, III, Partner, Ulmer & Berne LLP, USA
14:55-15:10 Coffee Break

© 2003-2018 All rights reserved by BIT Congress Inc.
Contact Us: Tel: 0086-411-84799609, Fax: 0086-411-84796897